Hematology 2020

AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
62nd ASH® Annual Meeting and Exposition

Editors

Adam Cuker, MD, MS
Executive Editor, Hematology 2020
Associate Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Mario Cazzola, MD
Deputy Editor, Hematology 2020
Research Group Leader on Myeloid Neoplasms
Fondazione IRCCS Policlinico San Matteo and University of Pavia
Pavia, Italy

Stella T. Chou, MD
Deputy Editor, Hematology 2020
Associate Professor of Pediatrics
The Children’s Hospital of Philadelphia
University of Pennsylvania
Philadelphia, PA

Ann LaCasce, MD, MSc
Deputy Editor, Hematology 2020
Associate Professor of Medicine
Dana-Farber Cancer Institute
Boston, MA

David Garcia, MD
Special Section Editor, Hematology 2020
Professor of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA
Contents

x Editors’ Message
xi Reviewers
xii Continuing Medical Education Information

Ham-Wasserman Lecture

1 Therapeutic development and current uses of BCL-2 inhibition
   ANDREW W. ROBERTS

A Map for the Changing Landscape of CLL

10 Approaches for relapsed CLL after chemotherapy-free frontline regimens
   LINDSEY E. ROEKER AND ANTHONY R. MATO

18 EVIDENCE-BASED MINIREVIEW
   Treatment of relapsed chronic lymphocytic leukemia after venetoclax
   MEGHAN C. THOMPSON AND ANTHONY R. MATO

24 Chemotherapy-free frontline therapy for CLL: is it worth it?
   JOANNA M. RHODES AND JACQUELINE C. BARRIENTOS

33 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy
   CAROL MORENO

Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?

41 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
   EVAN C. CHEN AND JACQUELINE S. GARCIA

51 How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia
   ALISON R. WALKER

57 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
   EUNICE S. WANG AND JEFFREY BARON

Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders

67 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry
   RITA SELBY

76 Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders
   MICHELE P. LAMBERT

82 EVIDENCE-BASED MINIREVIEW
   Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura
   ANG LI AND JOHANNA A. KREMER HOVINGA
Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?

85 Can we use epigenetics to prime chemoresistant lymphomas?
JENNIFER E. AMENGUAL

95 Harnessing lymphoma epigenetics to improve therapies*
HAOPENG YANG AND MICHAEL R. GREEN

101 Novel targets in aggressive lymphoma
KAMI MADDOCKS

Beyond the Marrow

107 Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes
CARMEM BONFIM

115 Extrahematopoietic manifestations of the short telomere syndromes
KRISTEN E. SCHRATZ

Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?

123 Optimizing management of acute leukemia in community centers and when to refer
ANAND P. JILLELLA, JORGE E. CORTES, AND VAMSI K. KOTA

129 Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
ANNA B. HALPERN AND ROLAND B. WALTER

135 Updates in infection risk and management in acute leukemia
C. LOGAN, D. KOURA, AND R. TAPLITZ

Challenging Situations for Patients with Aggressive Lymphomas

140 Approaches to aggressive B-cell lymphomas in less fit patients
NANCY L. BARTLETT

148 Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
OREOFE O. ODEJIDE

154 Strategies for aggressive T-cell lymphoma: divide and conquer
LAUREN C. PINTER-BROWN

Chronic Transfusion Support: Challenging Cases

160 Challenges in chronic transfusion for patients with thalassemia
ASHUTOSH LAL

167 Outpatient transfusions for myelodysplastic syndromes
ERICA M. WOOD AND ZOE K. McQUIL TEN

175 Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life
JENNIFER WEBB

Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time?

184 Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?
WEE-SHIAN CHAN

190 When I treat a patient with acute pulmonary embolism at home
FREDERIKUS A. KLOK AND MENNO V. HUISMAN

195 EVIDENCE-BASED MINIREVIEW
Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism
RADHIKA GANGARAJU AND FREDERIKUS A. KLOK
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
FIONNUALA N´I ´AINLE AND BARRY KEVANE

Genetic Testing for Heritable Hematologic Disorders 101

Informed consent for genetic testing in hematology
JONATHAN M. MARRON

Identifying potential germline variants from sequencing hematopoietic malignancies
IRA L. KRAFT AND LUCY A. GODLEY

Handling Challenging Questions in the Management of CML

First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
VIVIAN G. OEHLER

How to manage CML patients with comorbidities
JORGE CORTES

Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
DELPHINE REA

Immunotherapy in Multiple Myeloma

Sequencing multiple myeloma therapies with and after antibody therapies
NIELS W. C. J. VAN DE DONK

EVIDENCE-BASED MINIREVIEW
Should all newly diagnosed MM patients receive CD38 antibody–based treatment?
CHARLOTTE L. B. M. KORST AND NIELS W. C. J. VAN DE DONK

Bispecifics, trispecifics, and other novel immune treatments in myeloma
GUIDO LANCMAN, JOSHUA RICHTER, AND AJAI CHARI

Future of CAR T cells in multiple myeloma
KITSADA WUDHIKARN, SHAM MAILANKODY, AND ERIC L. SMITH

Improving Symptom Control for Children with Hematological Malignancies

Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies
LILLIAN SUNG, TAMARA P. MILLER, AND ROBERT PHILLIPS

Indolent Lymphomas: Answers to Smoldering Questions

How do I sequence therapy for follicular lymphoma?
GILLES SALLES

How do we sequence therapy for marginal zone lymphomas?
ALESSANDRO BROCCOLI AND PIER LUIGI ZINZANI

Transformed lymphoma: what should I do now?
SONALI SMITH

Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis

Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
ELISSA R. ENGEL AND JOLAN E. WALTER
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases

LUIS MALPICA AND STEPHAN MOLL

Preventing infections in children and adults with asplenia

GRACE M. LEE

Managing Toxicities of Targeted Therapies in CLL

Managing toxicities of Bruton tyrosine kinase inhibitors

ANDREW LIPSKY AND NICOLE LAMANNA

Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors

ASHLEY HANLON AND DANIELLE M. BRANDER

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia

KIRSTEN FISCHER, OTHMAN AL-SAWAF, AND MICHAEL HALLEK

Monoclonal Gammopathies of Determined Significance

Management of AL amyloidosis in 2020

GIOVANNI PALLADINI, PAOLO MILANI, AND GIAMPAOLO MERLINI

Management of Waldenström macroglobulinemia in 2020

JORGE J. CASTILLO AND STEVEN P. TREON

Monoclonal gammapathies of clinical significance

ANGELA DISPENZIERI

More Anxiety-Provoking Hematology Consults

A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact

ARI ZIMRAN, ROSA RUCHLEMER, AND SHOSHANA REVEL-VILK

Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease

KENNETH MCCLAIN

Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP

MICHAEL LINENBERGER AND KLEBER Y. FERTRIN

Myelodysplastic Syndromes: What We Have and What We Want

Existing agents, novel agents, or transplantation for high-risk MDS

BART L. SCOTT

Patient stratification in myelodysplastic syndromes: how a puzzle may become a map

ANNE SOPHE KUBASCH AND UWE PLATZBECKER

Therapy for lower-risk MDS

HETTY E. CARRAWAY AND CANER SAYGIN

Myeloproliferative Disorders: Too Many Cells, Too Few Therapies

Applied genomics in MPN presentation

ALISON R. MOLITerno AND HANNAH KAIZER

Genomics of MPN progression

ANAND A. PATEL AND OLATOYOSI ODENIKE
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
MRINAL M. PATNAIK AND TERRA L. LASHO

EVIDENCE-BASED MINIREVIEW
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review
MRINAL M. PATNAIK AND TERRA LASHO

Out of Balance: Anemias Due to Disordered Iron Homeostasis

Inherited microcytic anemias
MARIA DOMENICA CAPPELLINI, ROBERTA RUSSO, IMMACOLATA ANDOLFO, AND ACHILLE IOLASCON

Global look at nutritional and functional iron deficiency in infancy
MICHAEL B. ZIMMERMANN

Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?
KLEBER YOTSUMOTO FERTRIN

Pediatric Hematological Malignancies: CARs for Kids

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
EMILY M. HSIEH AND RAYNE H. ROUCE

CAR T cells for other pediatric non-B-cell hematologic malignancies
ADAM J. LAMBLE AND REBECCA GARDNER

CAR T cells vs allogeneic HSCT for poor-risk ALL
CAROLINE DIORIO AND SHANNON L. MAUDE

EVIDENCE-BASED MINIREVIEW
What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?
AIMEE C. TALLEUR AND SHANNON L. MAUDE

Platelet Transfusions for Hematology/Oncology Patients

Does ABO and RhD matching matter for platelet transfusion?
NANCY M. DUNBAR

How well do platelets prevent bleeding?
DARRELL J. TRIULZI

EVIDENCE-BASED MINIREVIEW
The use of premedications for platelet transfusions in pediatric patients
MEGHAN MCCORMICK AND DARRELL TRIULZI

Platelet transfusion refractoriness: How do I diagnose and manage?
CLAUDIA S. COHN

Selected Hemostasis and Thrombosis Topics in Women

Management of heavy menstrual bleeding on anticoagulation
BETHANY SAMUELSON BANNOw

EVIDENCE-BASED MINIREVIEW
Abnormal uterine bleeding in users of rivaroxaban and apixaban
AMANDA E. JACOBSON-KELLY AND BETHANY T. SAMUELSON BANNOw

Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management
CLAIRE McLINTOCK
Women and bleeding disorders: diagnostic challenges
PAULA D. JAMES

The Brain and Pain in Sickle Cell Disease
Neuropathic pain in sickle cell disease: measurement and management
ALEXANDER GLAROS AND AMANDA M. BRANDOW
Optimizing the management of chronic pain in sickle cell disease
IFEYINWA OSUNKWO, HAZEL F. O’CONNOR, AND ELNA SAAH

The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
Next-generation cell therapies: the emerging role of CAR-NK cells
RAFET BASAR, MAY DAHER, AND KATAYOUN REZVANI
Practical aspects of building a new immunotherapy program: the future of cell therapy
JESÚS G. BERDEJA

Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma
Fundamentals of immunology for understanding immunotherapy for lymphoma
STEPHEN M. ANSELL
Immunotherapy with cells*
ELISE A. CHONG AND DAVID L. PORTER
Immunotherapy with drugs
YUN CHOI AND CATHERINE S. DIEFENBACH

Nonanticoagulant Interventions in Venous Thromboembolism
Role of venous stenting for venous thromboembolism
KAREN BREEN
Thrombolytic therapy in acute venous thromboembolism
THITA CHIASAKUL AND KENNETH A. BAUER
Inferior vena cava filters: a framework for evidence-based use
AMAR H. KELKAR AND ANITA RAJASEKHAR
EVIDENCE-BASED MINIREVIEW
Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?
AMAR H. KELKAR AND ANITA RAJASEKHAR

What Hematologists Need to Know About Giving and Stopping Aspirin
Does aspirin prevent venous thromboembolism?
ROBERT DIEP AND DAVID GARCIA
Combining antiplatelet and anticoagulant therapy in cardiovascular disease
GEOFFREY D. BARNES

Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
EMMA C. MORRIS
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation
ROSHINI S. ABRAHAM
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)
MARKUS G. SEIDEL
Erratum

680 Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019;2019: 381-390.

*Articles Not Eligible for Continuing Medical Education Credit

95 Harnessing lymphoma epigenetics to improve therapies
   Haopen GYang and Michael R. Green

590 Immunotherapy with cells
   Elise A. Chong and David L. Porter
Editors' Message

Welcome to the 62nd annual meeting of the American Society of Hematology. This year’s congress is unique among ASH annual meetings—the first to be all-virtual and the first to be held in the midst of a raging pandemic.

And just as the annual meeting has had to adapt to the circumstances, so too has Hematology 2020. For the first time, this year’s edition is electronic-only. Some of the chapters reference COVID-19 and its impact on hematologic disorders. Other new features include a new page design, visual abstracts, and shorter manuscripts with the aim of making Hematology more graphical.

In spite of these changes, the essence of Hematology remains the same. As always, you can count on high quality content spanning the breadth of malignant and nonmalignant hematology, based on a state-of-the-art Education Program prepared by this year’s Education Co-Chairs, Dr. Sioban Keel and Dr. Christopher Flowers. Dr. Andrew Roberts will deliver the Ham-Wasserman Lecture on Therapeutic Development and Current Uses of BCL-2 Inhibition, and his article is also included.

This volume is the culmination of the efforts of many individuals and their selfless commitment to ASH, including the authors, reviewers, designer (Debra Naylor), and ASH staff (Michelle Lee, Kenneth April, and Brian Cannon).

In these difficult times, we hope that you find Hematology to be the valued resource that it has always strived to be: a means of helping you keep current with the torrid pace of progress in hematology by highlighting recent practice-changing clinical advances as well as putting cutting edge basic advances into clinical context. Happy reading, and please stay safe.

Adam Cuker, MD
Mario Cazzola, MD
Stella T. Chou, MD
Ann LaCasce, MD
David Garcia, MD
Reviewers

The editors thank the session chairs and the reviewers who worked hard to ensure the reliability of the material presented in Hematology 2020:

Roshini Abraham*
Ranjana Advani
Dominick Amato
Jennifer Amengual*
David Anderson
Stephen Ansell*
Donald Arnold
Daria Babushok
Michele Baccarani
Manisha Balwani
Jacqueline Barrientos*
Matthew Barth
Shannon Bates
Kenneth Bauer
Vijaya Bhatt
Danielle Brander
Elizabeth Brem
Jennifer Brown
Maria Cappellini*
Hetty Carraway*
C. Patrick Carroll
Leandro Cerchietti
Michael Choi
Michele Ciboddo
Joan Cid
Adam Cohen
Peter Collins
Raffaella Colombatti
Catherine Coombs
Steven Coutre
Andrew Cowan
Susan Creary
Nicholas Cross
Mark Crowther
Amy Davidoff
Matthew Davids
Matteo Della Porta
Thomas DeLoughery
Jenny Despotovic
Madhav Dhodapkar
James Douketis
Areej El-Jawhari
Elihu Estey
Andrew Evans
Amir Fathi
Jean-Paul Fermand
Mark Fleming
Christopher Flowers
David Garcia*
Rebecca Gardner
Francesca Gay
William Geerts
James George
Neelam Giri*
Lisa Giulino-Roth
Lucy Godley*
Rachael Grace
Peter Greenberg
Jacob Grinfeld
Peter Gross
Anna Halpern*
Paul Hacker-Murray
Andreas Hochhaus
Boyu Hu
David Hui
Robert Hurley*
Nitin Jain
Andra James
David Jimenez
Cassandra Josephson
Brad Kahl
Manali Kamdar
Efstathios Kastritis
Richard Kaufman
Neil Kay
Sioban Keel
Rami Komrokji
Peter Kouides
Amrita Krishnan
Ashish Kumar
Ashutosh Lal*
Nicole Lamanna*
Michele Lambert*
Marcel Levi
Franco Locatelli
Izidore Lossos
Keith McCrae
Saskia Middeldorp*
Alison Moliterno*
Stephan Moll*
Emma Morris
Aziz Nazha
Ellis Neufeld
Fionnuala Ni Ainle*
Oreofe Odejide*
Timothy Olson
Adam Olszewski
Ifeyinwa Osunkwo*
Roger Owen
Monica Pagano
Julie Panepinto
Sant-Rayn Pasricha
Krina Patel
Mary-Elizabeth Percival
Barbara Pro
Michael Pulsipher
Elizabeth Raetz
Anita Rajasekhar*
Leo Rasche
Jay Raval
Katayoun Rezvani*
Rachel Rosovsky
Rayne Rouce*
Elisa Rumi
Gilles Salles*
Martin Schipperus*
Mikkael Sekeres
Mazyar Sekeres
Nirali Shah
Leslie Skeith
Tyler Smith
Sarah Spinler
David Steensma
Stephan Stilgenbauer
Michael Streiff
Jeffrey Szer*
Monica Thakar
Magnus Tobiasson
Christopher Tormey
Darrell Triulzi*
Suresh Vedanthan
Ajay Vora
Alison Walker*
Jennifer Webb*
Ashutosh Wechalekar
Angela Weyand
Marianne Yee
Amer Zeidan
Michelle Zeller

* indicates Session Chair
Continuing Medical Education Information

Hematology: the ASH Education Program, is an annual publication that provides practicing hematologists with invaluable information on the most important areas of clinical progress.

Hematology 2020 is a peer-reviewed collection of 92 articles written by the 2020 ASH Education Program speakers and the Ham-Wasserman Lecturer. The papers showcase groundbreaking advances and new concepts in 30 different fields. Every year, the periodical provides an updated and comprehensive review of each of the topics covered in the annual meeting education sessions.

Educational objectives
1. Employ the knowledge gained regarding the diagnosis and treatment of malignant and nonmalignant hematologic disorders to improve patient care.
2. Discuss the state-of-the-art therapeutics in hematology.
3. Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of malignant and non-malignant hematologic disorders.

Date of release
December 2020

Date of expiration
On December 31, 2021, the ability to earn Continuing Medical Education (CME) credit and American Board of Internal Medicine Maintenance of Certification Medical Knowledge points for this product expires. This is the last date for users to claim credit for this product. For questions about credit, please contact the ASH Education Department at cme@hematology.org or call toll-free 866-828-1231 within the United States only; 1-202-776-0544 internationally.

Accreditation and credit designation
The American Society of Hematology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Hematology designates this enduring material for a maximum of 40 AMA Category 1 PRA Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who participate in this CME activity but are not licensed in the United States are also eligible for AMA Category 1 PRA Credit™. To earn these credits, readers must pass two online tests (malignant and non-malignant) based on chapters from the book.

ABIM Maintenance of Certification
Successful completion of this CME activity enables the participant to earn up to 40 Medical Knowledge points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME credits and ABIM points
The estimated time to complete this educational activity is 40 hours. To claim CME credit, users must complete an evaluation of the product and a test of medical knowledge, both of which are accessed through the ASH Academy (academy.hematology.org). There is a one-time processing fee for claiming CME/MOC credit. Users with scores of 80% or better on these self-assessment modules are eligible to claim credit for the activity.

To facilitate claiming of credit, the test for this product is divided into two subtests, one of which focuses on malignant hematology content with the other focusing on nonmalignant content. Successful completion of each test earns the user 20 AMA Category 1 PRA Credits™. Users claim CME and/or ABIM MOC credit for each test individually. You can take one or both tests, depending on your CME and MOC needs.

Each test consists of 25 questions. The 25 questions can be answered in one sitting, or a user can save their progress and return to complete the test at a later time.

The Malignant Hematology Test covers information presented in the following sections:
- A Map for the Changing Landscape of CLL
- Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?
- Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
- Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?
• Challenging Situations for Patients with Aggressive Lymphomas
• Handling Challenging Questions in the Management of CML
• Immunotherapy in Multiple Myeloma
• Improving Symptom Control for Children with Hematological Malignancies
• Indolent Lymphomas: Answers to Smoldering Questions
• Managing Toxicities of Targeted Therapies in CLL
• Monoclonal Gammopathies of Determined Significance
• Myelodysplastic Syndromes: What We Have and What We Want
• Myeloproliferative Disorders: Too Many Cells, Too Few Therapies—How Do We Choose?
• Pediatric Hematological Malignancies: CARs for Kids
• The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
• Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma

The Nonmalignant Hematology Test covers information presented in the following sections:

• Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders
• Beyond the Marrow: Major Nonhematologic Complications of Inherited Bone Marrow Failure Syndromes
• Chronic Transfusion Support: Challenging Cases
• Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time?
• Genetic Testing for Heritable Hematologic Disorders 101
• Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis Needs when Treating Nonmalignant Hematologic Disorders—Wash Your Hands and What Else?
• More Anxiety-Provoking Hematology Consults
• Out of Balance: Anemias Due to Disordered Iron Homeostasis
• Platelet Transfusions for Hematology/Oncology Patients: Taking a More Granular Look
• Selected Hemostasis and Thrombosis Topics in Women
• The Brain and Pain in Sickle Cell Disease: Understanding the Role of Sensory, Cognition, and Neuropathic Pathways in the SCD Chronic Pain Experience
• Updates on the Role of Nonanticoagulant Interventions in Venous Thromboembolism
• What Hematologists Need to Know About Giving and Stopping Aspirin
• Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology